Login to Your Account



Teva, Active stop high dose of MS drug after heart troubles surface

By Michael Fitzhugh
Staff Writer

Monday, January 4, 2016

Teva Pharmaceutical Industries Ltd. and Active Biotech AB said that testing of 1.2 mg and 1.5 mg doses of the experimental multiple sclerosis (MS) therapy laquinimod have been discontinued in two ongoing studies of the drug after eight patients experienced non-fatal cardiovascular (CV) events.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription